The PRV sale and KRESLADI approval remove near-term financing risk and validate the platform, but the stock's next major catalyst is the FDA alignment on completing the Danon disease pivotal trial, expected in H2 2026. Monitor for the investor webinar and regulatory update on RP-A601 in PKP2-ACM.
Drugs in focus
RCKT drug pipeline →KRESLADI
● Neutral Named in this 8-K- Impact
- Phase
- Approved (FDA accelerated approval)
- Time to market
- Already FDA-approved (March 26, 2026); commercial launch underway
- Next catalyst
- None dated
What to watchKRESLADI's approval and the $180M PRV sale provide a cash runway into Q2 2028, but the drug is an ultra-orphan gene therapy with a "minimal viable launch", not a major revenue generator. Watch the company's cardiovascular pipeline (RP-A501 for Danon disease, RP-A701 for BAG3 cardiomyopathy) for future catalysts. RCKT carries heavy short interest (~25.5% of float), a squeeze risk if pipeline data hits, but the clinical hold history on RP-A501 adds risk.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 11 $3.50entry
- T+1 · 3mo ago −2.57%α −2.82% · $3.41
- T+5 · 3mo ago −4.57%α −4.17% · $3.34
- T+20 · 2mo ago +3.71%α +4.77% · $3.63
- T+60 · 13d ago −25.43%α −24.94% · $2.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rocket Pharmaceuticals reported Q2 2026 GAAP net income of $123.2M ($1.09 basic EPS), driven by a $178.2M gain from the sale of its Priority Review Voucher (PRV), compared to a net loss of $68.9M in Q2 2025. Operating loss improved to $46.9M from $71.1M on lower R&D and G&A expenses. The company ended the quarter with $283.7M in cash, extending runway into Q2 2028, and reported positive safety data from the first three Danon disease patients in the pivotal Phase 2 trial of RP-A501.
Key Financial Metrics
Key Facts
- GAAP net income of $123.2M in Q2 2026 vs net loss of $68.9M in Q2 2025, primarily due to $178.2M gain from PRV sale.
- Cash, cash equivalents, and investments of $283.7M as of June 30, 2026, up from $188.9M at Dec 31, 2025, extending runway into Q2 2028.
- All three initial patients in the pivotal Phase 2 trial of RP-A501 for Danon disease completed the safety observation period with no TMA, capillary leak syndrome, or other significant safety concerns.
- KRESLADI (marnetegragene autotemcel) received FDA accelerated approval for severe LAD-I; commercial availability and patient onboarding expected to begin in Q4 2026.
- Operating loss improved to $46.9M from $71.1M year-over-year, driven by lower R&D and G&A expenses.
Financial Impact
Net income of $123.2M vs net loss of $68.9M YoY; cash position strengthened by $94.8M sequentially to $283.7M
Risk Factors
- KRESLADI is a first commercial launch for the company; adoption and reimbursement timelines are uncertain.
- Danon disease pivotal trial completion depends on FDA alignment; any delays or safety signals in additional patients could reset the timeline.
- Operating expenses, while reduced, still consume cash; the company remains pre-revenue from product sales until KRESLADI launches.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-032028 |
| Document: ef20079821_8k.htm | 0001140361-26-032028 |
| Document: 0001140361-26-032028-index-headers.html | 0001140361-26-032028 |
| Document: 0001140361-26-032028-index.html | 0001140361-26-032028 |
| Document: 0001140361-26-032028.txt | 0001140361-26-032028 |
| 8-K Data (Synthetic) | 0001140361-26-032028 |
Track record
21 reports on RCKT
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +42.18% at T+20 after the Jun 12, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.45 Now $2.16 −11.84% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $2.30 Now $2.16 −6.09% settles Dec 14
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $2.53 Now $2.16 −14.62% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $2.44 Now $2.16 −11.29% settles Dec 4
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $2.44 Now $2.16 −11.48% settles Nov 30
- Oct 6, 20265w ago 8-K Bullish 7/10 Entry $2.54 to $2.57 Now $2.16 −14.79% ▲ +1.38% +2.62% vs SPY
- Sep 15, 20268w ago 8-K Bullish 7/10 Entry $3.41 to $2.30 Now $2.16 −36.66% ▼ −32.55% −35.27% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers